Veraxa Health

Veraxa Health is a biotechnology company specializing in the rapid discovery and development of next-generation antibody-drug conjugates (ADCs) and functional antibodies. The company utilizes a proprietary microfluidic droplet-based screening platform that allows for the ultra-high-throughput analysis of millions of single B-cells to identify rare functional antibodies in days rather than months. Additionally, Veraxa employs a site-specific conjugation technology based on click chemistry to ensure precise drug-to-antibody ratios and improved therapeutic windows. By combining rapid discovery with advanced engineering, the company aims to accelerate the development of precision oncology treatments. Veraxa operates both an internal pipeline and provides technology access to pharmaceutical partners.